Newron Pharmaceuticals S.p.A.

NWPHF · OTC
Analyze with AI
12/31/2024
6/30/2024
12/31/2023
6/30/2023
Operating Activities
Net Income$30,951-$9,557-$9,274-$6,950
Dep. & Amort.$96$96$99$102
Deferred Tax$0$0$0$1,361
Stock-Based Comp.$86$170$142$55
Change in WC-$38,221$468$958-$22
Other Non-Cash-$1,698-$5$3,538$1,212
Operating Cash Flow-$8,786-$8,828-$4,537-$5,603
Investing Activities
PP&E Inv.-$6-$7-$3-$8
Net Acquisitions$0$0$0$0
Inv. Purchases-$1,875$0$0$0
Inv. Sales/Matur.$5,046$0$0$0
Other Inv. Act.-$2,016$2,016$3,260-$3
Investing Cash Flow$1,149$2,009$3,257-$11
Financing Activities
Debt Repay.$97-$97$0-$97
Stock Issued$15,414$0$0$0
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.-$8,838$8,475-$95$0
Financing Cash Flow$6,673$8,378-$95-$97
Forex Effect$0$0-$6,338$13,424
Net Chg. in Cash-$964$7,897-$7,713$7,713
Supplemental Information
Beg. Cash$7,897$0$7,713$0
End Cash$6,933$7,897$0$7,713
Free Cash Flow-$8,792-$8,835-$4,540-$5,611